Monday, September 23, 2019
- 1:45pm-3:15pm
-
Variants in the beta-Glucocerebrosidase A (GBA) gene in German patients with Parkinson´s disease
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Vortioxetine treatment of depression in Parkinson’s disease
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting
Other · Agora 2 West, Level 2
- 1:45pm-3:15pm
-
Wearable versus marker-free technologies: does it matter for clinical gait analysis?
Other · Agora 2 West, Level 2
- 1:45pm-3:15pm
-
WES analysis of Parkinson’s disease patients with Cancer
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
What connectivity tells us about neurodegeneration in Huntington disease? A fMRI study
Huntington’s Disease · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
What do medical students think about functional movement disorders?
Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
What patients need – a qualitative analysis of consultations prior to deep brain stimulation in patients with Parkinson’s disease
Quality of Life · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Whole Exome Sequencing Identifies a Homozygous POLG2 Missense Variant in an adult patient presenting with movement disorders and Mitochondrial DNA Depletion
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Wide distribution of alpha-synuclein oligomers in Creutzfeldt-Jakob disease detected by a novel proximity ligation assay
Other · Agora 2 West, Level 2